+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route of Administration, Therapy Line, Mechanism of Action, Formulation - Global Forecast to 2030- Product Image
Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route of Administration, Therapy Line, Mechanism of Action, Formulation - Global Forecast to 2030- Product Image
Sale

Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route of Administration, Therapy Line, Mechanism of Action, Formulation - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6017361
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Generic Oncology Drugs Market grew from USD 38.74 billion in 2024 to USD 41.51 billion in 2025. It is expected to continue growing at a CAGR of 6.95%, reaching USD 58.01 billion by 2030.

Revolutionizing Cancer Care with Accessible Generic Treatments

The evolution of the generic oncology drugs sector underscores a profound shift in global health priorities and pharmaceutical innovation. As patent expiries converge with an increasing demand for cost-effective cancer treatments, this segment has emerged as a critical pillar of modern therapeutic arsenals. Gone are the days when access to oncology medications hinged solely on brand-name portfolios; today, generics offer comparable efficacy and safety profiles while alleviating financial burdens on healthcare systems worldwide.

In this landscape, manufacturers are leveraging advanced formulation techniques to replicate complex biologics and optimize small molecule production. Regulatory authorities have responded by streamlining approval pathways, accelerating time-to-market without compromising quality standards. Meanwhile, healthcare providers and payers have heightened their focus on value-based care models, reinforcing the role of generics in delivering budget-conscious yet clinically robust solutions.

As these dynamics converge, the generic oncology market stands at an inflection point, where innovation, affordability, and regulatory alignment must coalesce. This report lays the groundwork for understanding the forces reshaping this space, setting the stage for strategic decision-making in an increasingly competitive environment.

Embracing Innovation and Policy Shifts to Redefine Industry Standards

The contours of the generic oncology market have been redrawn by seismic transformations in technology, policy, and collaborative research. Biotechnological breakthroughs now enable the biomanufacture of complex monoclonal antibodies and personalized cell therapies at scale, eroding barriers that once confined such innovations to high-cost branded pipelines. Concurrently, digital platforms are reshaping supply chains, harnessing real-time data analytics for improved forecasting, inventory management, and distribution efficiency.

Regulatory reforms have also been instrumental. Accelerated approval mechanisms and harmonized international guidelines have reduced redundant testing requirements, enabling generics and biosimilars to enter key markets more swiftly. Public-private partnerships and philanthropic initiatives have further catalyzed access programs in underserved regions, underscoring a commitment to equitable oncology care.

Meanwhile, emerging business models-ranging from subscription-based pricing agreements to outcome-linked reimbursement structures-are redefining value propositions across the stakeholder ecosystem. In this era of transformative change, organizations must adopt agile strategies to harness new technologies, navigate evolving policies, and forge impactful collaborations that drive both growth and patient outcomes.

Assessing the Strategic Consequences of US Tariff Revisions in 2025

Tariff adjustments slated for 2025 will imprint a significant influence on the United States generic oncology market, reshaping cost structures and competitive dynamics. By imposing additional duties on select imported active pharmaceutical ingredients and finished formulations, these measures aim to incentivize domestic manufacturing while responding to broader trade policy objectives.

Manufacturers with integrated US facilities stand to benefit from supply chain resilience and reduced duty burdens, enabling them to offer greater price stability. Conversely, companies reliant on cross-border sourcing may confront elevated production costs, compelling them to reassess supplier networks and invest in localized capacity. Payers and healthcare systems could experience transient price fluctuations, potentially impacting formulary decisions and reimbursement policies.

Importantly, the tariff environment will also catalyze strategic differentiation. Organizations that proactively negotiate supplier agreements or accelerate technology transfer initiatives can mitigate cost pressures and preserve market share. As 2025 approaches, stakeholders must conduct rigorous scenario analyses, stress-testing financial projections against varied tariff outcomes to ensure robust contingency planning.

Unveiling Growth Catalysts Through In-Depth Segmentation Analysis

A nuanced understanding of market segmentation reveals where growth and competitive intensity will converge. Within the drug type spectrum, small molecule generics maintain a strong foothold thanks to well-established manufacturing processes, while biosimilar biologics emerge as a high-value frontier supported by advanced cell culture capabilities. In indications such as breast and lung cancers, robust pipeline activity and entrenched treatment protocols drive steady demand, whereas therapies targeting colorectal and prostate cancers hinge on evolving diagnostic rates and screening initiatives.

Distribution channels further delineate performance contours: hospital pharmacies capture the critical mass of inpatient therapies, online pharmacies unlock patient convenience and extended reach, and retail pharmacies serve as pivotal points for ambulatory care. The route of administration likewise shapes development priorities; oral formulations appeal to outpatient compliance, whereas intravenous and subcutaneous delivery methods cater to hospital-based and specialized clinic environments.

Therapy line segmentation underscores the premium associated with first-line generics, where clinical endorsement and guideline inclusion confer accelerated uptake, while second-line and later-stage treatments reflect shifting patient tolerability and resistance profiles. Mechanism of action layers add additional texture; chemotherapeutic agents remain foundational, immunotherapy subsegments such as CAR-T and checkpoint inhibitors capture transformative outcomes, and targeted therapies including monoclonal antibodies and tyrosine kinase inhibitors offer precise intervention. Finally, formulation science-spanning liquid vials, lyophilized powders, and oral tablets-illuminates opportunities to differentiate on stability, administration convenience, and storage efficiencies.

Mapping Regional Variations to Drive Market Penetration

Regional performance patterns reveal distinct demand drivers and competitive landscapes. In the Americas, established healthcare infrastructure and aggressive generic adoption policies underpin strong volume growth, with United States dynamics setting a global benchmark for pricing and reimbursement negotiations. The Europe, Middle East & Africa region exhibits a mosaic of regulatory environments, where mature Western European markets converge with high-potential emerging economies, each demanding tailored market entry and commercialization strategies.

Asia-Pacific stands out for its dynamic expansion, fueled by rising cancer incidence rates, expanding healthcare coverage, and government incentives to domestic production. In Japan, stringent quality standards elevate biosimilar acceptance, while China’s evolving patent framework and preferential procurement schemes accelerate local generics. Across these regions, cross-border partnerships and capacity-building initiatives play a pivotal role in bridging supply gaps and fostering sustainable growth trajectories.

Profiling Market Leaders and Their Strategic Playbooks

A review of leading players highlights strategic investments that define the competitive frontier. Key manufacturers are expanding biologics fermentation capacity, forging alliances with contract development organizations to streamline biosimilar production, and integrating digitized manufacturing lines to enhance batch traceability. Strategic mergers and acquisitions have consolidated portfolios, enabling companies to achieve scale efficiencies and broaden their oncology franchise across multiple therapeutic classes.

Moreover, innovative collaborations between pharmaceutical firms and technology solution providers are optimizing clinical trial designs, expediting comparative bioavailability studies, and reducing time-to-market. Concurrently, organizations are strengthening their commercial footprints through targeted marketing campaigns, engaging key opinion leaders, and establishing value demonstration frameworks that resonate with payers. As these players refine their competitive positioning, smaller regional manufacturers are capitalizing on niche segments and leveraging government incentives to fortify local market share.

Transform Insights into Decisive Actions for Sustained Growth

Industry leaders must act decisively to transform insights into tangible outcomes. First, investing in flexible manufacturing platforms will allow swift adaptation to shifting regulatory landscapes and tariff structures, ensuring uninterrupted supply. Second, prioritizing the development of high-margin biosimilars and complex generics can generate differentiated revenue streams, elevating profitability and market relevance.

Third, forging end-to-end partnerships across the value chain-from ingredient suppliers to logistics providers-will bolster resilience against geopolitical and operational disruptions. Fourth, leveraging advanced analytics to segment payers, providers, and patients will sharpen pricing strategies and optimize portfolio deployment. Finally, cultivating a culture of continuous innovation-through open innovation models, academic collaborations, and internal R&D incubation-will sustain long-term competitive advantage and improve patient access globally.

Leveraging a Robust Multimodal Research Approach

This analysis draws upon a multifaceted research methodology combining primary interviews with industry executives, regulatory experts, and clinical stakeholders alongside secondary data from peer-reviewed journals, government publications, and proprietary databases. Qualitative insights were triangulated with quantitative metrics to validate market trends and competitive dynamics.

A rigorous segmentation framework was applied, evaluating drug type, indication, distribution channel, route of administration, therapy line, mechanism of action, and formulation to uncover nuanced performance differentials. Regional analyses incorporated policy reviews and trade impact assessments to model the effects of forthcoming tariff adjustments. Company profiles emerged from financial disclosures, patent filings, and press releases to ensure a holistic view of strategic priorities and operational capabilities.

This comprehensive approach ensures the conclusions and recommendations herein rest on a solid evidentiary foundation, equipping decision-makers with actionable intelligence to chart a course in the generic oncology drugs market.

Synthesis of Strategic Imperatives in an Evolving Market

The generic oncology drugs sector stands at a critical juncture, where technological innovation, regulatory reform, and shifting trade policies intersect to shape the future of cancer care. By understanding the transformative shifts driving biologic and small molecule generics, quantifying the impact of US tariffs, and dissecting market segments down to mechanism of action and formulation, stakeholders can craft strategies that maximize return on investment and patient benefit.

Regional insights underscore the need for market-specific approaches, as the Americas, Europe, Middle East & Africa, and Asia-Pacific each present unique regulatory and commercial dynamics. Leading organizations that prioritize manufacturing flexibility, portfolio differentiation, and strategic partnerships will outpace competitors and deliver sustainable value.

In sum, the convergence of affordability imperatives and clinical innovation creates unprecedented opportunities for those who act with foresight and agility. This report illuminates the path forward, providing the clarity and guidance required to navigate a complex and rapidly evolving market landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Type
    • Biologics
    • Small Molecule
  • Indication
    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Prostate Cancer
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Therapy Line
    • First-Line
    • Second-Line
    • Third-Line Plus
  • Mechanism Of Action
    • Chemotherapy
    • Immunotherapy
      • CAR-T Therapy
      • Checkpoint Inhibitors
    • Targeted Therapy
      • Monoclonal Antibodies
      • Tyrosine Kinase Inhibitors
  • Formulation
    • Liquid
    • Lyophilized Powder
    • Tablet
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Pfizer Inc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Viatris Inc
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Generic Oncology Drugs Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.3. Small Molecule
9. Generic Oncology Drugs Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Leukemia
9.5. Lung Cancer
9.6. Lymphoma
9.7. Prostate Cancer
10. Generic Oncology Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Generic Oncology Drugs Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Generic Oncology Drugs Market, by Therapy Line
12.1. Introduction
12.2. First-Line
12.3. Second-Line
12.4. Third-Line Plus
13. Generic Oncology Drugs Market, by Mechanism of Action
13.1. Introduction
13.2. Chemotherapy
13.3. Immunotherapy
13.3.1. CAR-T Therapy
13.3.2. Checkpoint Inhibitors
13.4. Targeted Therapy
13.4.1. Monoclonal Antibodies
13.4.2. Tyrosine Kinase Inhibitors
14. Generic Oncology Drugs Market, by Formulation
14.1. Introduction
14.2. Liquid
14.3. Lyophilized Powder
14.4. Tablet
15. Americas Generic Oncology Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Generic Oncology Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Generic Oncology Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Teva Pharmaceutical Industries Ltd
18.3.2. Sandoz International GmbH
18.3.3. Pfizer Inc
18.3.4. Fresenius Kabi AG
18.3.5. Hikma Pharmaceuticals PLC
18.3.6. Viatris Inc
18.3.7. Dr. Reddy’s Laboratories Ltd
18.3.8. Aurobindo Pharma Limited
18.3.9. Sun Pharmaceutical Industries Limited
18.3.10. Cipla Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. GENERIC ONCOLOGY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. GENERIC ONCOLOGY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. GENERIC ONCOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GENERIC ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. GENERIC ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GENERIC ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 67. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 68. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 70. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 117. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 125. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 133. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 134. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 149. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 152. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 153. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 160. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 161. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 189. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 197. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 207. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 212. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 213. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 215. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 222. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 224. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 243. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 244. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 245. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 249. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 251. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 252. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 253. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 258. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 259. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 260. TURKEY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 270. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 271. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 276. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 278. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 279. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 280. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 284. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 285. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 286. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 287. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 307. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 308. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 309. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 312. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 313. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 314. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 315. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 316. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 317. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 318. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 321. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 322. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 323. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 324. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 325. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 326. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 327. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. JAPA

Companies Mentioned

The companies profiled in this Generic Oncology Drugs market report include:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Pfizer Inc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Viatris Inc
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 41.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 58.01 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Generic Oncology Drugs Market Report 2025 - Product Image

Generic Oncology Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033 - Product Image

Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033

  • Report
  • 139 Pages
  • Global
From
Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast to 2030 - Product Image

Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Specialty Generics Market by Product Type, Drug Delivery System, Molecule Type, Disease Indication, Distribution Channel - Global Forecast to 2030 - Product Image

Specialty Generics Market by Product Type, Drug Delivery System, Molecule Type, Disease Indication, Distribution Channel - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Generic Oncology Sterile Injectable Market Report 2025 - Product Image

Generic Oncology Sterile Injectable Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Generic Oncology Drug Market

The Generic Oncology Drug market is a subset of the larger Generic Drug market. Generic Drugs are copies of brand-name drugs that have the same active ingredients, dosage form, strength, route of administration, safety, efficacy, and intended use as the original drug. Generic Oncology Drugs are used to treat cancer and are typically much less expensive than their brand-name counterparts. Generic Oncology Drugs are typically available in oral, injectable, and topical forms. Generic Oncology Drugs are subject to the same regulatory standards as brand-name drugs, and must meet the same safety and efficacy requirements. Generic Oncology Drugs are typically available in the same dosage forms and strengths as their brand-name counterparts. Some companies in the Generic Oncology Drug market include Mylan, Teva Pharmaceuticals, Sandoz, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.